A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body
← catalyst calendarSponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
44actual
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-11 | actual | When the study began enrolling |
| Primary completion | 2025-11-21 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-21 | actual | The whole study's end, after follow-up |
| First posted | 2026-02-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Overweight and Obesity
Intervention
- Drug: AMG 133 — also filed as Maridebart cafraglutide
Primary outcomes
what the primary-completion date above is the date OFMaximum Observed Concentration (Cmax) of AMG 133
measured Up to Day 120
Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of AMG 133
measured Up to Day 120
AUC From Time 0 Extrapolated to Infinity (AUCinf) of AMG 133
measured Up to Day 120
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed